Quarterly report pursuant to Section 13 or 15(d)

Reverse Recapitalization - Schedule of Reverse Recapitalization (Details)

v3.21.2
Reverse Recapitalization - Schedule of Reverse Recapitalization (Details) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended
Jun. 18, 2021
Sep. 30, 2021
Sep. 30, 2020
Jan. 13, 2021
Cash proceeds from Crescent        
Crescent’s cash in trust account $ 253,395      
Crescent’s cash and cash equivalents 20      
Less: redemptions (155,372)      
Cash proceeds from PIPE Investment 75,000      
Cash proceeds from Forward Purchase Agreement 25,000      
Less: Cash payments to escrow (2,000)      
Less: Cash payments to stockholder representative expense holdback (100)      
Less: Cash payments of Merger transaction costs (38,560)      
Net cash proceeds from Merger and PIPE financing 157,383 $ 157,383 $ 0  
Merger transaction costs not impacting additional paid-in capital 2,308      
Non-cash VCIP/OBIP stock bonus 32,637      
Non-cash net assets assumed from Crescent 36      
Non-cash offering cost associated with warrant liability 41 $ 41 $ 0  
Less: warrant liability (2,008)      
Net contribution from Merger and PIPE financing $ 190,397      
Class A common stock issued (in shares) 7,500,000      
Per share price on the Closing Date (in dollars per share) $ 10.00      
Class A Common Stock, Forward Purchase Agreement        
Cash proceeds from Crescent        
Class A common stock issued (in shares) 2,500,000      
Per share price on the Closing Date (in dollars per share) $ 10.00      
Forward Purchase Warrant        
Cash proceeds from Crescent        
Warrants issued (in shares) 833,333     833,333